CLINICAL TRIALS PROFILE FOR TRAVASOL 5.5% IN PLASTIC CONTAINER

All Clinical Trials for TRAVASOL 5.5% IN PLASTIC CONTAINER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02032953 ↗	Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia	Active, not recruiting	Canadian Institutes of Health Research (CIHR)	Phase 4	2013-12-01	The purpose of this study is to find out whether adding insulin after current colorectal cancer surgery promotes making and keeping proteins in the body, and to find out whether or not this effect can be further increased by increasing the amount of protein given.
NCT02032953 ↗	Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia	Active, not recruiting	McGill University Health Center	Phase 4	2013-12-01	The purpose of this study is to find out whether adding insulin after current colorectal cancer surgery promotes making and keeping proteins in the body, and to find out whether or not this effect can be further increased by increasing the amount of protein given.
NCT02032953 ↗	Enhancing the Anabolic Effect of Perioperative Nutrition With Insulin While Maintaining Normoglycemia	Active, not recruiting	McGill University Health Centre/Research Institute of the McGill University Health Centre	Phase 4	2013-12-01	The purpose of this study is to find out whether adding insulin after current colorectal cancer surgery promotes making and keeping proteins in the body, and to find out whether or not this effect can be further increased by increasing the amount of protein given.
NCT00313807 ↗	Study of Intravenous Amino Acid Infusion to Prevent Contrast Dye Mediated Renal Damage	Withdrawn	Queen's University	Phase 2	2005-11-01	Exposure to radiographic contrast dye during coronary angiography is well known to cause either transient decreases in renal function or acute renal failure. Although the overall incidence is low, acute renal failure occurs most frequently in patients with both diabetes and chronic renal failure where the average reported incidence is upwards of 20%. The etiology of contrast-induced nephropathy is related to acute decline in renal blood flow following dye exposure resulting in ischemic injury at the level of the medulla. The development of acute renal failure following radiocontrast dye administration is significant because it contributes to morbidity and mortality in patients at risk. The administration of amino acids, either through intravenous infusion or a protein meal, results in a substantial increase in renal plasma flow (RPF) and glomerular filtration rate (GFR). In both healthy subjects and in those with chronic renal failure, an amino acid infusion produces a 20% rise in GFR and effective RPF. We hypothesize that the 20% rise in effective RPF and GFR following an amino acid infusion will counteract the radiocontrast dye-induced vasoconstriction and reduce the renal toxicity of contrast medium in a group of high-risk patients.

Clinical Trial Conditions for TRAVASOL 5.5% IN PLASTIC CONTAINER

Condition Name

Condition Name for TRAVASOL 5.5% IN PLASTIC CONTAINER
Intervention	Trials
Colorectal Cancer	1
Contrast Nephropathy	1
Renal Failure	1

Condition MeSH

Condition MeSH for TRAVASOL 5.5% IN PLASTIC CONTAINER
Intervention	Trials
Colorectal Neoplasms	1
Renal Insufficiency	1
Kidney Diseases	1

Clinical Trial Locations for TRAVASOL 5.5% IN PLASTIC CONTAINER

Trials by Country

+

−

Trials by Country for TRAVASOL 5.5% IN PLASTIC CONTAINER
Location	Trials
Canada	1

Clinical Trial Progress for TRAVASOL 5.5% IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for TRAVASOL 5.5% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for TRAVASOL 5.5% IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Active, not recruiting	1
Withdrawn	1

Clinical Trial Sponsors for TRAVASOL 5.5% IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for TRAVASOL 5.5% IN PLASTIC CONTAINER
Sponsor	Trials
McGill University Health Centre/Research Institute of the McGill University Health Centre	1
Queen's University	1
Canadian Institutes of Health Research (CIHR)	1

Sponsor Type

Sponsor Type for TRAVASOL 5.5% IN PLASTIC CONTAINER
Sponsor	Trials
Other	4

Clinical Trials, Market Analysis, and Projections for TRAVASOL 5.5% in Plastic Containers

Introduction

TRAVASOL, an amino acid injection, is a critical component in parenteral nutrition, particularly for patients who are unable to eat properly due to illness or surgery. This article will delve into the current clinical trials landscape, market analysis, and future projections for TRAVASOL 5.5% packaged in plastic containers.

Clinical Trials and Usage

Overview of TRAVASOL

TRAVASOL is a solution of essential amino acids used intravenously to provide nutritional support. It is available in various concentrations, including the 5.5% solution, which is often used in clinical settings[2][4].

Clinical Studies

While specific clinical trials focused solely on TRAVASOL 5.5% in plastic containers are not widely reported, the product's stability and safety have been evaluated in various studies. For instance, the stability of TRAVASOL in plastic containers has been confirmed through tests that ensure the solution remains effective and safe for use within the specified expiration period[2].

Market Analysis

Global Market for Parenteral Nutrition

The market for parenteral nutrition solutions, including amino acid injections like TRAVASOL, is driven by the increasing need for nutritional support in clinical settings. This market is influenced by factors such as the growing number of patients requiring intravenous nutrition due to various medical conditions.

Plastic Containers Market

The use of plastic containers for pharmaceutical products, including TRAVASOL, is on the rise due to several advantages. Plastic containers are more cost-effective, lightweight, and resistant to leakage compared to traditional glass containers. The global plastic containers market is projected to grow from $218.04 billion in 2024 to $344.79 billion by 2032, at a CAGR of 5.9%[5].

Specifics of TRAVASOL Packaging

TRAVASOL 5.5% is packaged in plastic containers, specifically in VIAFLEX plastic containers, which are fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). These containers are designed to minimize moisture loss and protect the solution from external factors such as temperature and light[2].

Market Projections

Growth Drivers

The market for TRAVASOL and similar parenteral nutrition solutions is expected to grow due to several factors:

• Increasing Demand for Parenteral Nutrition: The rising number of patients requiring intravenous nutritional support due to illnesses or surgeries will drive the demand for products like TRAVASOL.
• Advancements in Packaging Technology: Improvements in plastic container technology, such as enhanced recyclability and the use of sustainable materials, will continue to support the growth of the market[3][5].

Regional Market Analysis

• Asia Pacific: This region is expected to be a significant contributor to the growth of the plastic containers market, driven by the expanding healthcare and pharmaceutical industries in countries like China and India[5].
• North America: The U.S. is a leading market for parenteral nutrition solutions, with a strong healthcare infrastructure and significant investment in research and development. This region is expected to continue driving demand for products packaged in plastic containers[3][5].

Clinical Trial Packaging Market

Relevance to TRAVASOL

While TRAVASOL itself is not typically involved in clinical trials as a new drug entity, the broader context of clinical trial packaging is relevant. The clinical trial packaging market, which includes the packaging of investigational products like new formulations or delivery systems for existing drugs, is growing at a CAGR of 10.80% from 2024 to 2034. This growth is driven by the need for advanced, patient-friendly, and informative packaging solutions[3].

Key Takeaways

• Stability and Safety: TRAVASOL 5.5% in plastic containers has been shown to be stable and safe for use.
• Market Growth: The market for parenteral nutrition solutions and plastic containers is expected to grow significantly over the next decade.
• Regional Demand: Asia Pacific and North America are key regions driving the demand for these products.
• Packaging Advancements: Improvements in plastic container technology will continue to support market growth.

FAQs

What is TRAVASOL 5.5% used for?

TRAVASOL 5.5% is an amino acid injection used intravenously to provide essential amino acids for patients who are unable to eat properly due to illness or surgery.

What type of containers are used for TRAVASOL 5.5%?

TRAVASOL 5.5% is packaged in VIAFLEX plastic containers made from a specially formulated polyvinyl chloride (PL 146 Plastic).

How is the market for TRAVASOL 5.5% expected to grow?

The market for TRAVASOL 5.5% and similar parenteral nutrition solutions is expected to grow due to increasing demand for intravenous nutritional support and advancements in packaging technology.

What are the key regions driving the demand for TRAVASOL 5.5%?

Asia Pacific and North America are the key regions driving the demand for TRAVASOL 5.5% and other parenteral nutrition solutions.

What are the benefits of using plastic containers for TRAVASOL 5.5%?

Plastic containers are more cost-effective, lightweight, and resistant to leakage compared to traditional glass containers, and they protect the solution from external factors such as temperature and light.

Sources

1. AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024 - AbbVie News.
2. Travasol (Amino Acids (Injection)) - RxList.
3. Clinical Trial Packaging Market Size, Growth Rate 10.80% - Towards Packaging.
4. TRAVASOL (amino acids) injection, for intravenous use - FDA.
5. Plastic Containers Market Size, Share | Growth Report [2032] - Fortune Business Insights.